Ikarian Capital’s Structure Therapeutics GPCR Stock Holding History

Ikarian Capital’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,824	Closed	-$336K	–	186
2025 Q4	$336K	Sell	4,824 -158,413	-97%	-$6.47M	0.03%	147
2025 Q3	$4.57M	Sell	163,237 -19,848	-11%	-$395K	0.46%	52
2025 Q2	$3.8M	Sell	183,085 -81,000	-31%	-$1.78M	0.73%	42
2025 Q1	$4.57M	Sell	264,085 -20,000	-7%	-$490K	0.56%	40
2024 Q4	$7.7M	Buy	284,085 +168,885	+147%	+$5.99M	1.05%	22
2024 Q3	$5.06M	Buy	+115,200	New	+$4.45M	0.71%	38
2024 Q1	–	Sell	-14,524	Closed	-$612K	–	158
2023 Q4	$592K	Sell	14,524 -123,300	-89%	-$7.07M	0.06%	113
2023 Q3	$6.95M	Buy	+137,824	New	+$4.44M	0.84%	35

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ikarian Capital's GPCR Position: Q1 2026 in Review

Ikarian Capital sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 4,824 shares — an estimated $336K sold.

Ikarian Capital first reported a position in GPCR in Q3 2023 and held it in 8 quarters. The position peaked at $7.7M in Q4 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Ikarian Capital reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
Ikarian Capital sold 4,824 Structure Therapeutics shares in Q1 2026, an estimated $336K.
Ikarian Capital first reported a position in Structure Therapeutics in Q3 2023 and held it in 8 quarters.
Ikarian Capital's Structure Therapeutics position peaked at $7.7M in Q4 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.